Metagenomi Therapeutics, Inc. MGX
1.15
0.00
0.00%
as of 25 Sep
- Market cap
- $43.4M
- P/E
- 0.0×
Follow MGX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.39 | 2.28 | 0.78 | 0.78 | 0.78 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(2.56) | (4.54) | (1.70) | (1.70) | (1.70) |
P/B ratio |
0.38 | 0.51 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.38 | 0.51 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(2.78) | (1.89) | (4.60) | (4.60) | (4.60) |
EV/EBITDA |
0.75 | 1.08 | 2.46 | 2.46 | 2.46 |
EV/Operating CF |
0.79 | 0.91 | 2.25 | 2.25 | 2.25 |
EV/FCF |
0.78 | 0.88 | 2.03 | 2.03 | 2.03 |
Quick Ratio |
7.03 | 6.69 | 3.97 | 7.46 | 4.30 |
Current Ratio |
7.22 | 6.91 | 4.04 | 7.56 | 4.33 |
Net Debt/EBITDA |
1.71 | 2.72 | 3.25 | 8.17 | 3.33 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 21.32% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.69 |
Asset Turnover |
0.09 | 0.15 | 0.11 | 0.06 | 0.00 |
Operating CF/Net income |
1.01 | 1.40 | 1.34 | (0.68) | (1.13) |
Capex/Depreciation |
(0.26) | 1.29 | 1.96 | (48.20) | (4.92) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (44.67%) | (157.26%) | 65.00% | 81.50% | 0.00% | |
| (32.20%) | (22.64%) | (17.52%) | (15.67%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(56.73%) | (32.74%) | (29.55%) | (13.02%) | (24.48%) |
Average Days of Receivables |
4.42 | 8.77 | 19.99 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
374.59% | 208.78% | 210.93% | 250.81% | 5,958.02% |
Selling, General and Administrative Expense of Revenue |
106.27% | 61.22% | 64.45% | 108.73% | 3,996.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
47.02% | 30.99% | 15.47% | 11.41% | 154.32% |
Graham Net Nets |
1.71 | 1.41 | 3.66 | 3.66 | 3.66 |
Graham Number |
0.00 | 0.00 | 134.01 | 0.00 | 0.00 |
Earnings Yield |
(146.30%) | (72.58%) | (194.43%) | (194.43%) | (194.43%) |
Free Cash Flow Yield |
(148.19%) | (94.09%) | (288.34%) | (288.34%) | (288.34%) |
Revenue per Share |
0.68 | 1.58 | 13.14 | 5.06 | 0.07 |
Operating CF per Share |
(2.39) | (3.30) | (26.85) | 8.74 | 7.45 |
Capex per Share |
(0.01) | (0.09) | (2.88) | (4.11) | (0.89) |
Free Cash Flow per Share |
(2.40) | (3.40) | (29.73) | 4.63 | 6.55 |
Cash per Share |
4.32 | 7.52 | 79.64 | 106.51 | 33.20 |
Shareholders Equity per Share |
4.26 | 7.11 | 63.19 | 79.90 | 13.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.26 | 7.11 | 63.19 | 79.90 | 13.49 |
Free Cash Flow |
(89.43) | (112.19) | (101.22) | 15.75 | 21.35 |
Working Capital |
142.61 | 220.65 | 209.41 | 318.36 | 83.74 |
Capital Expenditures |
(0.54) | (3.11) | (9.81) | (13.98) | (2.90) |
Net Current Asset Value |
103.03 | 168.22 | 128.61 | 224.09 | 10.88 |
EV/EBIT |
0.73 | 1.11 | 2.62 | 2.62 | 2.62 |
Capex to Sales |
0.02 | 0.06 | 0.22 | 0.81 | 11.95 |
Net Profit Margin |
(348.54%) | (149.26%) | (152.50%) | (253.45%) | (8,823.87%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.17 | (0.14) | (0.23) | 0.02 | 0.15 |
Cash ROIC |
(31.68%) | (26.25%) | (23.22%) | 2.08% | 11.18% |
Accounts Receivable Turnover |
32.28 | 28.21 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.78 | 1.85 | — | — | — |
Average Payables |
1.01 | 1.16 | 1.90 | 1.68 | — |
Average Assets |
272.85 | 344.72 | 389.66 | 278.24 | — |
Average Common Equity |
196.73 | 49.64 | (105.01) | (53.49) | — |
Columns are period end dates